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TO THE EDITOR
Photodynamic therapy (PDT) is based
on the concept that a certain photo-
activatable compound, called a photo-
sensitizer, can be excited by light of the
appropriate wavelength to generate
cytotoxic singlet oxygen and free radi-
cals (Hasan et al., 2006). Although
earlier reports of PDT involved micro-
biological applications (Raab, 1900),
clinically PDT has been developed
most extensively for oncologic and
ophthalmologic applications. Recent
clinical outcomes of PDT using
d-aminolevulinic acid (ALA)-induced
protoporphyrin IX (PpIX), termed
ALA-PDT, in patients with cutaneous
leishmaniasis (CL) have been promising
(Enk et al., 2003; Gardlo et al., 2003,
2004; Asilian and Davami, 2006), but
far from being curative.
ALA by itself is not a photosensitizer,
but is processed to PpIX in the heme
biosynthetic pathway where it serves as
a biological precursor of PpIX. It is
known that Leishmania amazonensis
parasites are deficient in seven out of
eight enzymes in the heme biosynthetic
pathway (Sah et al., 2002). Although
Leishmania major (L. major) have not
been studied for this enzyme defi-
ciency, as they require extracorporeal
supplementation with PpIX or hemin as
a growth factor in vitro (Steiger and
Steiger, 1976; Chang and Chang,
1985), it is reasonable to assume that
they may also be deficient in these
enzymes, and that they cannot produce
PpIX from ALA. Therefore, the reported
efficacy of ALA-PDT for CL is some-
what intriguing.
Encouraged by clinical reports, and
with a view to increasing the efficacy of
ALA-PDT for CL, we performed a series
of in vitro and in vivo experiments to
unravel the underlying mechanisms
associated with this clinical response.
In an attempt to better understand the
basis of ALA-PDT for CL, we identified
several key questions that are addressed
here: first of all, how does ALA-PDT
work for CL? At the cellular level, is
ALA-PpIX produced by Leishmania or
by host cells, or by both? Do Leishma-
nia parasites take up ALA-PpIX from
host cells?
We studied a series of cellular
events in Leishmania parasites and in
infected immortalized macrophages
(J774.2) during ALA-PDT. The amount
of PpIX in the stationary phase of a
Abbreviations: ALA, d-aminolevulinic acid; ALA-PDT, photodynamic therapy with 5-aminolevulinic
acid-induced protoporphyrin IX; ALA-PpIX, 5-aminolevulinic acid-induced protoporphyrin IX
CL, cutaneous leishmaniasis; PDT, photodynamic therapy; PpIX, protoporphyrin IX
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metacyclic parasite (3.0010177
0.21017 moles/cell) was 2.54-fold
greater than the amount of PpIX, which
could be accumulated by an amastigo-
te (7.6 101770.5 1017 moles/cell).
Amastigotes are different from promas-
tigotes in morphological, biochemical,
molecular, and antigenic phenotype, as
they assume the ability to grow at the
mammalian body temperature and to
infect the host’s cells (Schuster and
Sullivan, 2002). Amastigotes are phy-
siologically more active than promasti-
gotes and are likely to actively take up
more PpIX (Figure 1a and b). In spite of
this observation, the number of PpIX
molecules that one amastigote could acc-
umulate (4.6 10770.3 107 molecules/
cell) was still much lower than the
number of ALA-PpIX molecules required
for killing one metacyclic parasite
(2.31010 molecules/cell). ALA-PpIX
localized distinctively in amastigotes
in infected J774.2 cells at 4 hours co-
incubation with ALA, and furthermore,
the amastigotes in J774.2 cells were not
eliminated by ALA-PDT with light
doses up to 50 J/cm2 (data not shown).
These results would suggest that a good
clinical outcome in vivo is unlikely to
involve the direct killing of Leishmania
by ALA-PDT.
In contrast to the in vitro results,
which failed to demonstrate a parasiti-
cidal effect (Figure 1c and d), in in vivo
experiments in a murine CL model (all
animal procedures were performed
according to protocols approved by
the Massachusetts General Hospital
Subcommittee on Research Animal
Care), we observed a reduction of the
parasite load after ALA-PDT (Figure 1e).
Based on the fact that the uptake of
PpIX by the Leishmania was not enough
to kill the parasites, and that in vivo
ALA-PDT does reduce the parasite load,
it can be assumed that an alternative
indirect pathway is operational.
It is known that there are several
other mechanisms involved in tissue
damage by PDT (Luksiene, 2003). An
initial destruction of the vascular sys-
tem and the intracellular matrix is
followed by hypoxia, which results in
cell death. We speculated that the
vascular damage would have less effect
in PDT for CL as compared to PDT
against tumors with their abundant
vascularity. In our in vivo study, all of
the ALA-PDT treated ears demonstrated
a wedge-shaped necrosis in the
peripheral treatment area (Figure 1f,
arrows). As the PDT was performed
centrally to the lesion, the appearance
of a circular necrosis at the site of
irradiation could be expected. Anato-
mically, the blood supply of the murine
ear is composed of one major branched
blood vessel extending from base to
edge of the ear. Considering this, the
observed wedge-shaped distortion is
consistent with a lack of blood supply
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Figure 1. In vitro and in vivo efficacies of ALA-PDT against Leishmania. (a) The PpIX level in a parasite after co-incubation with exogenous PpIX or ALA
(0.1 mM). (b) Quantification of PpIX in an amastigote. (c–d) Exogenous PpIX mediated phototoxicity at high concentrations, whereas ALA did not. L. major
parasites were co-incubated with PpIX (c) or ALA (d) and subsequently irradiated at 10 J/cm2. The viability of parasites was determined as the percentage of
3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide conversion activity. (e) Intralesional quantification of L. major parasites by standard dilution (Belkaid
et al., 1998). *Po0.05 (f) Topical ALA-PDT on CL lesions 3 weeks after L. major infection (635 nM diode-laser at 50 J/cm2).
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resulting from vascular obstruction after
treatment.
On the other hand, the necrosis may
be the result of unspecific destruction of
the particular type of cells in the murine
CL lesion. In order to determine the
phototoxic effects of ALA-PDT on the
cellular components of CL lesions, we
estimated the percentage of neutrophils
(Ly-6G/Ly-6C), macrophages (F4/80),
T- (CD3) and B- (CD19) cells in the ears
of non-treated infected mice, treated
infected mice at 1 day after ALA-PDT,
and treated infected mice 7 days after
ALA-PDT. We observed that among
neutrophils, T- and B cells, the percen-
tage of macrophages was dramatically
decreased 7 days after ALA-PDT
(Figure 2a). This result suggests that
macrophages are the most sensitive to
ALA-PDT and would be the main target
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Figure 2. Phenotypic profile of cells in ears with CL lesions after ALA-PDT. (a) A representative dot plot (top left chart) used for cell gating (R1). Dot plots
for neutrophil (Ly-6G/Ly-6C), macrophage (F4/80), T lymphocyte (CD3), and B lymphocyte (CD19) expression are shown for infected untreated mice,
treated mice 1 day, and 7 days after ALA-PDT. (b) A representative dot plot displays SS and F4/80þ cells used for cell gating (R2). A dot plot for F4/80
and L. major surface glycoprotein (gp63-FITC) expression is shown in the middle. Tumor necrosis factor-a expression was determined in infected
(gp63-positive cells) and uninfected (gp63-negative cells) F4/80þ cells and presented as two charts on the right side of the picture.
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of this regimen. However, almost all
remaining macrophages (2.7%) were
infected (92.4%), providing a potential
source of future reactivation of the
infection (Figure 2b). The vast majority
of those infected macrophages pro-
duced tumor necrosis factor-a (97.7%),
compared to non-infected F4/80-posi-
tive cells, of which only 58.4% pro-
duced tumor necrosis factor-a. Thus,
one treatment is not sufficient for the
complete eradication of L. major-in-
fected cells.
The findings from this study suggest
that the clinical outcome observed with
ALA-PDT is likely the result of unspe-
cific tissue destruction accompanied by
a depopulation of macrophages rather
than any direct killing of parasites.
Other approaches, such as those study-
ing new photosensitizers, or PDT tar-
geted specifically against Leishmania,
may also be worth exploring.
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TO THE EDITOR
Pemphigus vulgaris (PV) is the most
common variant of the human auto-
immune blistering disorders in the
pemphigus complex and accounts for
over 80% of all cases (Greenberg,
1994). Although generally considered
as disease of middle-aged adults, PV
has also been reported in children and
neonates (Bjarnason and Flosadottir,
1999). In order to rapidly institute
appropriate therapeutic measures and
thus prevent the serious morbidity that
results from extensive loss of epidermal
cohesion, it is of importance to diag-
nose PV in its very initial phase.
PV is diagnosed by virtue of its
clinical and histological presentation,
the latter being examined on routine
paraffin-embedded biopsies. Characte-
ristically PV presents with fragile blis-
ters and subsequent erosions, matched
by suprabasal cleft formation and the
presence of acantholytic cells in light
microscopy. In early stages, diagnosis
may be missed in the presence of
nonspecific, pre-bullous inflammatory
skin lesions. Upon clinical suspicion of
PV, the demonstration of intraepider-
mal IgG deposits and circulating anti-
keratinocyte membrane antibodies by
direct (DIF) and indirect (IIF) immuno-
fluorescence, respectively, was manda-
tory to prove the autoimmune origin of
the disease until recently. DIF is carried
out on native tissue from the patient as
described by Beutner and Jordon (1964)
requiring a second biopsy in case the
first biopsy was solely processed
for routine histology. A commercially
Abbreviations: BP, bullos pemphigoid; DIF and IIF, direct and indirect immunofluorescence analysis;
Dsg3, desmoglein 3; PF, pemphigus foliaceus; PV, pemphigus vulgaris; SD, seborrheic dermatitis;
TEN, toxic epidermal necrolysis
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